In this tutorial, we introduce a differential equation simulation model for use in pharmacometrics involving NONMEM, Berkeley Madonna, and R. We report components of the simulation code and similarities/differences between software, rather than how to use each software. Depending on the purpose of the simulation, an appropriate tool can be selected for effective communication.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033377 | PMC |
http://dx.doi.org/10.12793/tcp.2017.25.3.125 | DOI Listing |
Ann Neurol
August 2024
Neuroscience Department, University of California, Berkeley, Berkeley, CA, USA.
Objective: Cross-sectional definitions of successful cognitive aging have been widely utilized, but longitudinal measurements can identify people who do not decline. We performed this study to contrast maintenance with declining trajectories, including clinical conversion.
Methods: We included baseline cognitively unimpaired Alzheimer's Disease Neuroimaging Initiative participants with 3 or more cognitive testing sessions (n = 539, follow-up 6.
Transl Clin Pharmacol
September 2017
Q-fitter Inc., 6th Floor, 412 Yeoksam-ro, Gangnam-gu, Seoul 06199, Korea.
In this tutorial, we introduce a differential equation simulation model for use in pharmacometrics involving NONMEM, Berkeley Madonna, and R. We report components of the simulation code and similarities/differences between software, rather than how to use each software. Depending on the purpose of the simulation, an appropriate tool can be selected for effective communication.
View Article and Find Full Text PDFClin Pharmacokinet
June 2013
Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Str 65, 88397 Biberach, Germany.
Background: Hemodialysis has been shown to be a useful method of decreasing dabigatran plasma levels in situations that require rapid elimination of this thrombin inhibitor. However, there is currently no clinical recommendation for the accelerated/optimized elimination of dabigatran via hemodialysis (e.g.
View Article and Find Full Text PDFClin Pharmacokinet
April 2010
Department of Clinical Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Background And Objective: Drugs undergoing enterohepatic circulation (EHC) are associated with typical pharmacokinetic characteristics such as multiple-peak phenomenon in the plasma concentration-time profile and prolongation of the apparent elimination half-life (t((1/2))). Currently, versatile pharmacokinetic models are lacking that could test the hypothesis of an EHC for observed multiple-peak phenomenon in pharmacokinetic profiles and its quantitative contribution. The aim of this analysis was to accomplish a model that is able to describe typical plasma concentration-time profiles of compounds undergoing EHC using data from intravenous studies of tesofensine and meloxicam.
View Article and Find Full Text PDFAAPS J
March 2007
Pharmacokinetics, Pharmacodynamics, and Bioinformatics, XOMA (US) LLC, Berkeley, CA 94710, USA.
An overview is provided of the present population analysis methods and an assessment of which software packages are most appropriate for various PK/PD modeling problems. Four PK/PD example problems were solved using the programs NONMEM VI beta version, PDx-MCPEM, S-ADAPT, MONOLIX, and WinBUGS, informally assessed for reasonable accuracy and stability in analyzing these problems. Also, for each program we describe their general interface, ease of use, and abilities.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!